Profiling of RNAi Regulation by Comparison in Cultured SH-Sy5y and U87 Cells: Response upon β Endorphin

In this study, it is postulated that there will be miRNA level changes which may be underlying within the cancer inhibitory mechanisms. Endorphins naturally exist as neurotransmitters, which are naturally degraded in polypeptide form. Therefore, this study focuses on profiling miRNA interactions with endorphin as a key growth-controlling factor in U87 glioblastoma and SH-Sy5y neuroblastoma cells. In brain tumors, glioblastoma (GBM) is an important tumor that has a prevalence in childhood over adults, whereas many other types of tumor have a high incidence after adolescence. It is a rare disease in terms of the epidemiology of tumor incidence by age group. The key role of synthetic endorphin in its RNA modification level is investigated in glioblastoma and neuroblastoma cell models by micro-RNA array profiling. Student’s t-test was used to evaluate the inhibitory effect of endorphin and its significant role in dose dose-dependent manner. ANOVA and Chi-square test were also applied to table sets in RNAi gene expression profile. Our findings indicate that endorphins have a highly skewed transcriptome processing profile in neuroblastoma as compared to glioblastoma. Also, cell viability decreased in Glioblastoma upon beta-endorphin treatment. It provides a transcriptional model for endorphin neurotransmitter effects with two human brain-derived cells. It is concluded that the proposed profiles will supplement a post-transcriptional genetic base for endocrine materials, which are poorly studied for drug resistance, conditions such as placebo response, neuroprotectivity and endorphin neurotransmitter effects of human brain-derived cells.